STAT+: AstraZeneca picks up FDA approval for hypertension drug

Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. Today we’re bringing you a special report: a fascinating look at how China’s growing role in global drug development is deeply dividing the U.S. biotech industry, with executives openly debating whether reliance on Chinese partners is a competitive necessity or a national security risk. Meanwhile, the FDA’s leadership shakeup has widened, with both CBER and CDER getting new acting directors, among other changes.Continue to STAT+ to read the full story…